CRC Monitor 腸追蹤

Test Report 檢驗報告

CellMax Life

檢測報告

CRC Monitor
腸追蹤

客戶資訊

申請者編號	883535
受檢者姓名	周明仁
身分證字號	B100034820
生日	1946/08/30
性別	男
受檢者連絡電話	0955-233946
電子信箱	
醫療院所	中山醫學大學附設醫院
醫療院所連絡電話	
醫師姓名	陳志毅
收檢日期	7/19/2018
報告日期	2019/10/03

檢測報告

CRC Monitor
腸追蹤

評估結果

Current CTC Count 目前循環腫瘤細胞顆數	2
Current CTC Trend 目前循環腫瘤細胞趨勢	低
Recommendation 建議	每三個月持續追蹤

備註

您目前的循環細胞腫瘤趨勢為低。建議您仍持續每三個月接受腸追蹤檢測。倘若期間您的健康出現任何變化，請立即尋求專業醫師的協助。

電子簽名

Leon Chen 陳律吾

Manager, Clinical Laboratory

2019/10/03

Date

Manana Kvezereli-Javey, MD, PhD

Medical Director, CellMax Inc

2019/10/03

Date

此檢測是由合度精密生物科技有限公司所研發設計。病患的治療或是照護不應該只單靠此檢測的結果而決定，因為並非所有的病患都做過大腸直腸癌完整的檢驗，如何將此檢測的結果運用在臨床治療，還是應該由醫師來決定。

檢測報告

CRC Monitor
腸追蹤

受檢者病史及生活型態

癌症種類 test

癌症分期 test

確診癌症的日期 test

備註
test

檢測歷史紀錄

Test Date/檢測日期	CTC counts/ 循環腫瘤細胞顆數
6/26/2017	18
8/8/2017	3
11/27/2017	1
7/19/2018	2



關於腸追蹤

腸追蹤是一種體外臨床檢測。運用專利的CMx平台，測量血液樣本中的生物腫瘤標記，也就是循環腫瘤細胞，來偵測大腸直腸癌復發 / 轉移。

適用對象

腸追蹤適用於已做過手術、或 / 和預防性治療的大腸直腸癌患者，作為定期追蹤大腸直腸癌是否復發或轉移的檢測。癌症是不停演變的疾病，持續追蹤、及早發現，是決定患者存活率的關鍵！在首次治療後的前三年，是復發/轉移的高風險期，建議病患每隔一至三個月，定期做追蹤檢測，以掌握治療的最佳時機。

腸追蹤的臨床使用

腸追蹤檢測結果解釋:

當循環腫瘤細胞趨勢顯示為"低"時，代表目前大腸直腸癌復發機率為低，而趨勢為"高"時，則為一警示訊號，須尋求更多醫療協助來確認癌症復發與否。少數病人的結果會落於循環腫瘤細胞趨勢目前無法判定的類別，表示趨勢不明確，因此仍建議持續每三個月檢測一次。









參考文獻

1. Hao-Wei Teng, et al. “A new classification scheme for recurrent or metastatic colon cancer after liver metastasectomy”. JCMA 74, p.493, 2011

2. Stewart BW, Wild CP, (Ed.). World Cancer Report 2014. International Agency for Research on Cancer, Lyon,France, 2014.

3. Chen et al, Int J Colorectal Dis. 2010 May;25(5):567-71.

4. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Wolff BG, Surg Gynecol Obstet. 1992 Jan; 174(1):27-32.

5. Millner et al. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013 Summer;43(3):295-304.

6. Nesteruk, et al. "Evaluation of Prognostic Significance of Circulating Tumor Cells Detection in Rectal Cancer Patients Treated with Preoperative Radiotherapy: Prospectively Collected Material Data." BioMed Research International, vol. 2014, Article ID 712827, 6 pages, 2014.

7. Shen et al, "Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker," Exp. Ther. Med; Volume 2 Issue 3; May 2011

8. Public domain image, National Cancer Institute, USA

9. Rahbari et al. "Meta-analysis Shows That Detection of Circulating Tumor Cells Indicates Poor Prognosis in Patients With Colorectal Cancer." Gastroenterology 2010;138:1714–1726

10.Marchetti et al. "Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients." J Gastrointestin Liver Dis, September 2014 Vol. 23 No 3: 279-284 2014

11.Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response,progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008 Jul;26 (19):3212-3221

12. Klein, et al. “Systemic spread is an early step in breast cancer,” Cancer Cell. 2008 Jan;13(1):5868

13. Yang et al. Epithelial–mesenchymal plasticity in carcinoma metastasis. Genes & Dev. 2013. 27: 2192-2206

14. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791

15. deBono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in the metastatic castration-resistant prostate cancer. Clin Cancer Res 2008 October 1;14(19):6302-6309

16.Budd TG, Cristofanilli M, Ellis MJ, et al: Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer. Clin Cancer Res 2006 12:6403-6409

Simple Blood Test. Real Time Protection. / 簡單的血液檢測，及時保護您！

CellMax Life

合度精密生物科技有限公司 / 合度醫事檢驗所

: 台北市115南港區園區街3號18樓之一 | 18F–1, No. 3 Park Street, Nangang, Taipei City, Taiwan

: 0800–555-885 : www.cellmaxlife.com